INTELLIA THERAPEUTICS, INC. (NASDAQ:NTLA) Files An 8-K Results of Operations and Financial Condition
Item 2.02.
On February27, 2019, Intellia Therapeutics, Inc. announced its financial results and business updates for the quarter and year ended December31, 2018. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 on this Current Report on Form8-K.
The information in this report furnished to Item 2.02 shall not be deemed filed for purposes of Section18 of the Securities Exchange Act of 1934, as amended (the Exchange Act), or otherwise subject to the liabilities of that section. It may only be incorporated by reference in another filing under the Exchange Act or the Securities Act of 1933, as amended, if such subsequent filing specifically references the information furnished to Item 2.02 of this report.
(d) Exhibits
| Press release dated February27, 2019 |
Intellia Therapeutics, Inc. Exhibit
EX-99.1 2 d712840dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Intellia Therapeutics Announces Fourth Quarter and Full-Year 2018 Financial Results – Confirmed improved non-human primate liver editing and protein reduction of greater than 95 percent in transthyretin amyloidosis program; investigational new drug application on track for 2020 submission – Engineered cell therapy platform will enable wholly owned development candidate for acute myeloid leukemia by year end – Demonstrated targeted insertion and genome editing in the liver of mice using proprietary DNA template designs – Ended 2018 with a strong cash position of $314 million CAMBRIDGE,…
To view the full exhibit click here
About INTELLIA THERAPEUTICS, INC. (NASDAQ:NTLA)
Intellia Therapeutics, Inc. is a genome editing company. The Company is focused on developing therapeutics utilizing a biological tool known as CRISPR/Cas9. The CRISPR/Cas9 genome editing system includes two components: the Cas9 protein and the guide RNA sequence. The Cas9 protein acts like a pair of molecular scissors that initiates the natural cellular repair process to knockout, repair or insert a gene. The guide RNA sequence recognizes and directs the Cas9 to a specific target deoxyribonucleic acid (DNA) sequence. The Company’s sentinel in vivo programs focus on the use of Lipid Nanoparticle (LNPs) for delivery of the CRISPR/Cas9 complex to the liver. The Company’s division, eXtellia Therapeutics, is focused on the application of CRISPR/Cas9 genome editing in the fields of immuno-oncology and autoimmune and inflammatory diseases. The Company’s subsidiary is Intellia Securities Corp. As of September 30, 2016, the Company had not generated any revenue.